Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Diluted Average) (2020 - 2025)

Crinetics Pharmaceuticals (CRNX) has 6 years of Shares Outstanding (Diluted Average) data on record, last reported at $94.1 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 16.43% year-over-year to $94.1 million; the TTM value through Dec 2025 reached $94.1 million, up 16.43%, while the annual FY2025 figure was $94.1 million, 16.43% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $94.1 million in Q4 2025 per CRNX's latest filing, roughly flat from $94.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $94.2 million in Q3 2025 and bottomed at $35.0 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $64.4 million, with a median of $56.8 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 48.75% in 2022, then increased 5.65% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $38.4 million in 2021, then skyrocketed by 35.24% to $52.0 million in 2022, then increased by 11.71% to $58.1 million in 2023, then skyrocketed by 39.11% to $80.8 million in 2024, then increased by 16.43% to $94.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $94.1 million in Q4 2025, $94.2 million in Q3 2025, and $93.8 million in Q2 2025.